About US
Contact us
-
Explanation found for high mortality in breast cancer patients taking aspirinResearchers from the University of North Carolina (UNC) at Chapel Hill, US, have identified that wide variations in the mortality risk of breast cancer patients taking aspirin could be related to2019/8/12
-
US court rules in favour of Amgen in Enbrel patent caseThe US District Court for the District of New Jersey has upheld two of Amgen’s patents that claim its rheumatoid arthritis drug Enbrel (etanercept) and methods for making the medicine. Amgen companie2019/8/9
-
China approves Gilead’s HIV-1 drug candidate BiktarvyThe China National Medical Products Administration (NMPA) has approved Gilead Sciences’ Biktarvy, a once-daily single-tablet regimen (STR) to treat HIV-1 infection. Biktarvy combines the integrase st2019/8/9
-
Canada announces changes to lower medicine pricesThe Government of Canada has made changes to its Patented Medicines Regulations, initially introduced in 1987, in a bid to lower prices of prescription medicines. These reforms are intended to cut do2019/8/8
-
AstraZeneca demonstrates Tagrisso’s superiority to other EGFR-TKI drugsAstraZeneca has published results from its Phase III FLAURA trial showing that in previously untreated patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) its drug Tagriss2019/8/8
-
Oric closes funding to develop glucocorticoid antagonist ORIC-101Oric Pharmaceuticals has closed a Series D financing to support the continued development of a clinical-stage, selective and potent glucocorticoid receptor antagonist, ORIC-101. The company is curren2019/8/7
-
Dynacure secures orphan drug designation from FDA for DYN101Dynacure has secured orphan drug designation from the US Food and Drug Administration (FDA) for investigational antisense medicine DYN101, which has been designed to modulate the expression of dynami2019/8/7
-
UF researchers focus on new drug candidate Apratoxin S4 to treat vision lossResearchers from the University of Florida (UF) College of Pharmacy have announced a partnership to focus on a new drug candidate Apratoxin S4 as a new method to prevent or treat vision loss. The res2019/8/6
-
NICE approves Keytruda combination therapy for NSCLC through CDFThe UK’s healthcare regulator the National Institute of Health and Care Excellence (NICE) has recommended Merck’s Keytruda (pembrolizumab) combined with two chemotherapy drugs, carboplatin and paclit2019/8/6
-
Takeda whittles away costs—and assets—to keep its debt-cutting promisesTakeda's been cutting costs on one hand and raising cash on the other to pay off its Shire deal debt—and so far, it's on track to hit those goals, executives said this week. The company's cost-saving2019/8/5